Quest Diagnostics (DGX)
NYSEHealth CareMedical - Diagnostics & ResearchSnapshot 2026-10-30
$251.82-0.43%
Close 2026-10-30 · 1-day change
NYSEHealth CareMedical - Diagnostics & ResearchSnapshot 2026-10-30
Research Workspace
Put DGX beside peers and holdings, graph the same metric, and keep your notes with the evidence.
Daily closes. Earnings/event dots are placed inline.
Industries move in repeating boom-and-bust cycles. This shows where this stock’s industry sits in that cycle, stage by stage (recovery → expansion → supercycle → steady → deceleration → contraction), from its fundamentals (orders, revenue, capital spending), not the stock’s price.
A booming industry is a tailwind for the names in it; a contracting one is a headwind. Companies in the same industry tend to rise and fall together with the cycle, the way a tide lifts and lowers every boat in the harbor at once, so a large part of a stock’s swing can come from where its industry sits rather than from the company itself. It’s context for reading the company’s results, not a buy/sell call. Full explanation →
Health Care is in steady. Describes the industry's cycle state, not a call on this stock.
The stage band shows the industry’s cycle over the chart’s timeline (each color a stage); a ▼ marks a quarter its growth inflected down — amber is an unconfirmed watch, red is confirmed the next quarter. Use “Overlay cycle on chart” to tint the price chart by stage. The industry’s fundamentals, not a signal on this stock.
The reason to own it still holds.
View ThesisRevenue growth is slowing — up about 9% over the past year and decelerating.
View GrowthRanks among the strongest in its industry on quality — around the top 18%.
View QualityManagement screens strong on earnings delivery, margins.
View ManagementExpectations look reasonable — what the market is pricing in sits in line with or below what analysts forecast.
View ValuationModerate volatility — typically moves about 1% a day.
View RiskDGX depends on continued revenue growth from consumer testing and diagnostic innovation. Revenue growth has eased from 10.2% to 10.0%, though the latest quarter beat. Shares trade at 23× P/E versus 22× for peers and 21× its history. Expectations look modest versus our growth view. Medicare lab fee cuts threaten that growth, and our model puts the next-quarter miss probability near 21%. Peer multiples imply a price about 18% below where it trades; our read remains intact, and this read is provisional.
Trailing returns as of 2026-10-30. DGX is total return (includes dividends); the S&P 500 benchmark is price return (the index excludes dividends).
Based on 18 analysts currently covering DGX (as of Oct 2026).
Based on 6 Wall Street analysts offering 12-month price targets for DGX in the last 4 months.
Continue this research
Compare DGX with peers and holdings, graph the same reported metric, keep your questions beside the evidence, and return when the facts change.
Compare now without an account. Saving and monitoring require an account.
| Compare | Company | Living FV | P/E | Revenue % | Quality |
|---|---|---|---|---|---|
| DGX Selected company | Graph | Compare | Trend | Review | |
| Peer Add a competitor | Graph | Compare | Trend | Review | |
| Holding Compare a holding | Graph | Compare | Trend | Review |
Selected metric trend
Quarterly · checked companies · value or % of revenue
A consensus fair price across 13 valuation methods, at three horizons. As of 2026-10-30. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
Today's peer multiple on trailing earnings, with no growth credited. This is the headline read.
Adds projected growth, so it leans optimistic by design. Read it as upside context, not a base case.
A price-focused, side-by-side fair-value read versus Health Care Services — fair value, gap to price, and forward P/E.
Compare the value case
Put DGX next to peers and holdings, compare Living FV and multiples, then graph the driver behind the difference.
Advances: Expand diagnostic innovations and Advanced Diagnostics
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
End-of-day figures as of 2026-10-30. EPS is implied from price ÷ P/E. Not investment advice.
Current $251.82
The last 12 months of price, then the range of analyst 12-month targets from today’s $251.82.
Analyst ratings and price targets are third-party Wall Street estimates, not QuarterlyIQ’s view. Not investment advice.
A long-thesis check that carries the widest uncertainty of the three horizons.
Above average on quality vs scored peers
Direction of the business behind the multiple. Bands are backend reads; trailing-12-month basis.
New Alzheimer’s test advances diagnostic innovation; strong Q3 supports growth, though the upgrade is analyst opinion.
Patient-record exposure creates privacy, regulatory, remediation, and reputational risks for a core lab operator.
Advances: Increase revenue growth
2026 revenue outlook and consumer-health growth projection support the revenue-growth objective.
Earnings and revenue exceeded estimates, supporting growth objectives and the intact thesis.
Threatens: Increase revenue growth
Medicare pricing headwind could impact revenue growth.
Threatens: Increase revenue growth
Medicare cuts could significantly impact revenue growth.
Advances: Increase revenue growth
Consumer testing growth supports revenue growth objectives.
Advances: Expand strategic collaborations and joint ventures
New testing push aligns with growth and strategic collaboration objectives.
